3,4-Diphenyl-3,4-dihydro-2H-1-benzopyran | 94866-41-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 3,4-Diphenyl-3,4-dihydro-2H-1-benzopyran
• 英文别名: 3,4-diphenyl-3,4-dihydro-2H-chromene
• CAS: 94866-41-8
• 化学式: C₂₁H₁₈O
• 分子量: 286.4
• InChiKey: FNIBSWRSKVEZDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Substituted thioacetamides
  申请人：——

  公开号：US20020183334A1

  公开（公告）日：2002-12-05

  The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.

  本发明涉及取代硫代乙酰胺的化学组合物、其制备方法以及在治疗疾病中使用这些组合物的用途。
• Use of 3,4-diphenyl chromans for the manufacture of a medicament for lowering cholesterol levels
  申请人：ELI LILLY AND COMPANY

  公开号：EP0672412A2

  公开（公告）日：1995-09-20

  The present invention provides novel methods of lowering serum cholesterol and inhibiting smoother muscle cell proliferation, particularly restenosis, in humans, and inhibiting uterine fibroid disease and endometriosis in women comprising administering to a human/woman in need of treatment an effective amount of a compound of formula I wherein R is C1-C6 alkyl, C1-C6 alkoxy, halo, or trifluoromethyl ; R1 and R2 each are the same or different C1-C6 alkyl group ; n is an integer from 2 to 6 ; and R3 and R4 each are independently C1-C4 alkyl, or combine to form a substituent selected from the group consisting of pyrrolidino, morpholino, piperidino, piperazino, 4-(C1-C6 alkyl)piperazino, and 4-phenyl-piperazino ; or a pharmaceutically acceptable salt thereof.

  本发明提供了降低人类血清胆固醇和抑制平滑肌细胞增殖，特别是再狭窄，以及抑制妇女子宫肌瘤疾病和子宫内膜异位症的新型方法，包括向需要治疗的人类/妇女施用有效量的式 I 化合物 其中 R 是 C1-C6 烷基、C1-C6 烷氧基、卤代或三氟甲基； R1 和 R2 各为相同或不同的 C1-C6 烷基； n 是 2 到 6 的整数；以及 R3和R4各自独立地为C1-C4烷基，或结合形成选自吡咯烷基、吗啉基、哌啶基、哌嗪基、4-(C1-C6烷基)哌嗪基和4-苯基哌嗪基组成的组的取代基；或其药学上可接受的盐。
• Use of 3,4-diphenyl chroman derivatives in the manufacture of a medicament for lowering serum cholesterol levels and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
  申请人：ELI LILLY AND COMPANY

  公开号：EP0976398A3

  公开（公告）日：2000-11-15

  The present invention provides novel methods of inhibiting smooth muscle cell proliferation, particularly restenosis, in humans, and inhibiting uterine fibroid disease and endometriosis in women comprising administering to a human/woman in need of treatment an effective amount of a compound of formula I whereinR is C1-C6 alkyl, C1-C6 alkoxy, halo, or trifluoromethyl;R1 and R2 each are the same or different C1-C6 alkyl group;n is an integer from 2 to 6; andR3 and R4 each are independently C1-C4 alkyl, or combine to form a substituent selected from the group consisting of pyrrolidino, morpholino, piperidino, piperazino, 4-(C1-C6 alkyl)piperazino, and 4-phenyl-piperazino; or a pharmaceutically acceptable salt thereof.

  本发明提供了抑制人类平滑肌细胞增殖，特别是再狭窄，以及抑制妇女子宫肌瘤疾病和子宫内膜异位症的新方法，包括向需要治疗的人类/妇女施用有效量的式I化合物 其中R是C1-C6烷基、C1-C6烷氧基、卤代或三氟甲基；R1和R2各自为相同或不同的C1-C6烷基；n为2至6的整数；R3和R4各自独立为C1-C4烷基，或结合形成选自吡咯烷基、吗啉基、哌啶基、哌嗪基、4-(C1-C6烷基)哌嗪基和4-苯基哌嗪基组成的组的取代基；或其药学上可接受的盐。
• Low dose modafinil for enhancement of cognitive function
  申请人：——

  公开号：US20010034373A1

  公开（公告）日：2001-10-25

  Modafinil is shown to be effective in improving or restoring cognitive function in the humans or other mammals when administered at doses that are substantially lower than optimal wakefulness-promoting doses. Daily dosages of less than 100 mg/day and more particularly from about 1 to about 75 mg/day are shown to be effective.

  莫达非尼的用药剂量大大低于促进清醒的最佳剂量时，可有效改善或恢复人类或其他哺乳动物的认知功能。每日用量少于100毫克，特别是约1至约75毫克/日的用量已被证明是有效的。
• Methods of treating and/or suppressing insulin resistance
  申请人：Endorecherche, Inc.

  公开号：US20040034000A1

  公开（公告）日：2004-02-19

  Novel methods for the medical treatment and/or prevention of obesity, abdominal fat, and insulin resistance in susceptible warm-blooded animals including humans involves the administration of selective estrogen receptor modulators (SERMs). A combination of a SERM with an amount of estrogen or a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3 b ,17 b -diol and compounds converted in vivo to one of the foregoing precursors or estrogen is also disclosed.

  用于治疗和/或预防包括人类在内的易感温血动物的肥胖症、腹部脂肪和胰岛素抵抗的新方法包括施用选择性雌激素受体调节剂（SERMs）。选择性雌激素受体调节剂与一定量的雌激素或选自脱氢表雄酮、硫酸脱氢表雄酮、雄-5-烯-3 b ,17 b -二醇以及在体内转化为上述前体之一或雌激素的化合物。